Business
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Sys
About this update from Volitionrx Limited
[{"type":"text","content":"HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in Japan.","length":732,"tagName":"p"},{"type":"text","content":"AMAMS 2025 is taking place in Thailand.","length":39,"tagName":"p"},{"type":"text","content":"Commenting on the results Dr Sato said:","length":39,"tagName":"p"},{"type":"text","content":""The Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool, particularly for differentiating between benign and malignant conditions such as Canine Chronic Enteropathy and Gastrointestinal Lymphoma."","length":217,"tagName":"p"},{"type":"text","content":"Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, added:","length":74,"tagName":"p"},{"type":"text","content":""We are delighted that leading veterinarian Dr Sato has adopted the Nu.Q® Vet Cancer Test in Japan, and not only researching, but publishing specific use cases. We believe this will further raise the awareness of the test and drive wider adoption."","length":264,"tagName":"p"},{"type":"text","content":"The presentations:","length":18,"tagName":"p"},{"type":"text","content":"Title: "Diagnostic Utility of Plasma Nucleosome Concentration in Differentiating Canine Chronic Enteropathy from Gastrointestinal Lymphoma" Presenter: Kentaro NabeshimaDate and Time: Thursday, June 5, 2025, 1:40PM – 1:50PM (ICT)Venue: Room 108Key Conclusion: Nu.Q® Vet Cancer Test may serve as a valuable diagnostic tool for distinguishing CE from GIL, with particularly high levels observed in medium-to-large cell GIL.Title: "Evaluation of Plasma Nucleosome Concentrations as a Biomarker for Canine Nasal Tumors"Presenter: Chihoko TakahashiDate and Time: Thursday, Ju...